Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lixte Biotechnology Holdings ( (LIXT) ) has provided an update.
On July 1, 2025, Lixte Biotechnology Holdings announced a $5 million private placement of shares, priced at market under Nasdaq rules, which includes Common Stock, Series B Convertible Preferred Stock, and Common Warrants. The transaction, expected to close on July 2, 2025, aims to raise funds for general corporate purposes and working capital, potentially boosting the company’s stockholders’ equity above $2.5 million, pending Nasdaq compliance determination.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is pioneering a new field of cancer biology known as activation lethality, with its lead compound, LB-100, which is a PP2A inhibitor that has shown potential to enhance chemotherapies and immunotherapies.
Average Trading Volume: 871,099
Technical Sentiment Signal: Sell
Current Market Cap: $3.17M
For detailed information about LIXT stock, go to TipRanks’ Stock Analysis page.